Characterization of regulatory T cells in patients with dermatomyositis

Journal of Autoimmunity

Volumn 35, Issue 4, 2010, Pages 342-350

  Antiga, E ^a   Kretz, C C ^b   Klembt, R ^b   Massi, D ^a   Ruland, V ^c   Stumpf, C ^b   Baroni, G ^a   Hartmann, M ^d   Hartschuh, W ^d   Volpi, W ^a   Del Bianco, E ^a   Enk, A ^d   Fabbri, P ^a   Krammer, P H ^b   Caproni, M ^a   Kuhn, A ^b,c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoimmune diseases; Cytokines; Dermatomyosits; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CD45RO ANTIGEN; CHEMOKINE RECEPTOR CCR4; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; CYTOKINE; FAS ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIGENS, CD4; BIOPSY; DERMATOMYOSITIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; SKIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 77958151436     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.07.006     Document Type: Article

References (46)

1. Kasteler J.S., Callen J.P. Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed. JAMA 1994, 272:1939-1941.
2. Stonecipher M.R., Jorizzo J.L., White W.L., Walker F.O., Prichard E. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: dermatomyositis sine myositis?. J Am Acad Dermatol 1993, 28:951-956.
3. Caproni M., Torchia D., Cardinali C., Volpi W., Del Bianco E., D'Agata A., et al. Infiltrating cells, related cytokines and chemokine receptors in lesional skin of patients with dermatomyositis. Br J Dermatol 2004, 151:784-791.
4. Hausmann G., Herrero C., Cid M.C., Casademont J., Lecha M., Mascaro J.M. Immunopathologic study of skin lesions in dermatomyositis. J Am Acad Dermatol 1991, 25:225-230.
5. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004, 22:531-562.
6. Shevach E.M. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002, 2:389-400.
7. Bluestone J.A., Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003, 3:253-257.
8. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
9. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
10. Taylor A., Verhagen J., Akdis C.A., Akdis M. T regulatory cells and allergy. Microbes Infect 2005, 7:1049-1055.
11. Nandakumar S., Miller C.W., Kumaraguru U. T regulatory cells: an overview and intervention techniques to modulate allergy outcome. Clin Mol Allergy 2009, 7:5.
12. Dieckmann D., Plottner H., Berchtold S., Berger T., Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001, 193:1303-1310.
13. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
14. Grant C., Oh U., Fugo K., Takenouchi N., Griffith C., Yao K., et al. Foxp3 represses retroviral transcription by targeting both NF-kappaB and CREB pathways. PLoS Pathog 2006, 2:e33.
15. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
16. Suri-Payer E., Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol 2006, 28:3-16.
17. Chatila T.A. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005, 116:949-959. quiz 60.
18. Cools N., Ponsaerts P., Van Tendeloo V.F., Berneman Z.N. Regulatory T cells and human disease. Clin Dev Immunol 2007, 2007:89195.
19. Costantino C.M., Baecher-Allan C.M., Hafler D.A. Human regulatory T cells and autoimmunity. Eur J Immunol 2008, 38:921-924.
20. Dejaco C., Duftner C., Grubeck-Loebenstein B., Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006, 117:289-300.
21. Loser K., Beissert S. Dendritic cells and T cells in the regulation of cutaneous immunity. Adv Dermatol 2007, 23:307-333.
22. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
23. Banica L., Besliu A., Pistol G., Stavaru C., Ionescu R., Forsea A.M., et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009, 42:41-49.
24. Franz B., Fritzsching B., Riehl A., Oberle N., Klemke C.D., Sykora J., et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007, 56:1910-1920.
25. Solomon G.J., Magro C.M. Foxp3 expression in cutaneous T-cell lymphocytic infiltrates. J Cutan Pathol 2008, 35:1032-1039.
26. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
27. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403-407.
28. Caproni M., Torchia D., Antiga E., Volpi W., del Bianco E., Fabbri P. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis. J Clin Immunol 2006, 26:370-375.
29. Fritzsching B., Oberle N., Eberhardt N., Quick S., Haas J., Wildemann B., et al. In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 2005, 175:32-36.
30. Klemke C.D., Fritzsching B., Franz B., Kleinmann E.V., Oberle N., Poenitz N., et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006, 20:1123-1129.
31. Krammer P.H. CD95's deadly mission in the immune system. Nature 2000, 407:789-795.
32. Hoogewerf A., Black D., Proudfoot A.E., Wells T.N., Power C.A. Molecular cloning of murine CC CKR-4 and high affinity binding of chemokines to murine and human CC CKR-4. Biochem Biophys Res Commun 1996, 218:337-343.
33. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., Sinigaglia F., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001, 194:847-853.
34. Fuhlbrigge R.C., Kieffer J.D., Armerding D., Kupper T.S. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997, 389:978-981.
35. Kuhn A., Beissert S., Krammer P.H. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 2009, 301:71-81.
36. de Boer O.J., van der Loos C.M., Teeling P., van der Wal A.C., Teunissen M.B. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem 2007, 55:891-898.
37. Kleinewietfeld M., Puentes F., Borsellino G., Battistini L., Rotzschke O., Falk K. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood 2005, 105:2877-2886.
38. Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005, 175:8392-8400.
39. Lee H.Y., Hong Y.K., Yun H.J., Kim Y.M., Kim J.R., Yoo W.H. Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:789-794.
40. Hirahara K., Liu L., Clark R.A., Yamanaka K., Fuhlbrigge R.C., Kupper T.S. The majority of human peripheral blood CD4+CD25highFoxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006, 177:4488-4494.
41. Amemiya K., Semino-Mora C., Granger R.P., Dalakas M.C. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000, 94:99-104.
42. Confalonieri P., Bernasconi P., Cornelio F., Mantegazza R. Transforming growth factor-beta 1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol 1997, 56:479-484.
43. Apostolou I., Verginis P., Kretschmer K., Polansky J., Huhn J., von Boehmer H. Peripherally induced Treg: mode, stability, and role in specific tolerance. J Clin Immunol 2008, 28:619-624.
44. Elst E.F., Klein M., de Jager W., Kamphuis S., Wedderburn L.R., van der Zee R., et al. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis. Arthritis Rheum 2008, 58:547-555.
45. Funauchi M., Shimadsu H., Tamaki C., Yamagata T., Nozaki Y., Sugiyama M., et al. Role of endothelial damage in the pathogenesis of interstitial pneumonitis in patients with polymyositis and dermatomyositis. J Rheumatol 2006, 33:903-906.
46. Hassan A.B., Fathi M., Dastmalchi M., Lundberg I.E., Padyukov L. Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 2006, 27:62-68.